/34 Good news on the #coronavirus #nCov19 front. BioNTech, partnering with $pfe, has been green-lit by BfArM to run an N=200 trial of a vaccine candidate, competing with CureVac and Moderna.

HT @MotherCabriniNY @rocket_jenross @boriquagato 

https://t.co/ACuQyvy7Lp